尼妥珠单抗治疗15例非小细胞肺癌临床疗效及不良反应的回顾性分析

目的回顾性分析尼妥珠单抗治疗晚期非小细胞肺癌（NSCLC）的临床疗效及不良反应。方法纳入15例经病理组织学或细胞学检查确诊的Ⅳ期NSCLC患者,其中腺癌9例,鳞状细胞癌8例。所有患者均接受尼妥珠单抗治疗（尼妥珠单抗400 mg,静脉滴注,每周1次）。每治疗6周后按照实体瘤疗效评价标准（RECIST）进行疗效评价,按照NCI-CTC 3.0标准评价不良反应。结果 15例患者均可评价药物安全性,其中11例可评价药物的客观疗效。在这11例患者中,疾病稳定（SD）8例,病情进展（PD）3例,疾病控制率为72.7%（8/11）;药物安全性评价结果显示尼妥珠单抗治疗相关的皮疹发生率低,且与临床获益无关;与尼妥珠单抗相关的不良反应轻。结论尼妥珠单抗联合化疗或放化疗能提高晚期NSCLC患者的疾病控制率,并且总体不良反应较轻。

The clinical outcomes and adverse events of nimotuzumab in advanced non-small cell lung cancer:a retrospective analysis with 15 cases

Objective To retrospectively analyze the therapeutic efficacy and adverse events of nimotuzumab in advanced non- small cell lung cancer（NSCLC）. Method Nimotuzumab was administrated to 15 cases of stage IV NSCLC, including 9 cases of adenocarcinoma and 8 cases of squamous cell carcinoma. All patients were confirmed by either histopathology or cytopathology, and were treated by nimotzumab（nimotuzumab 400 mg, i.v., qw）. The efficacy was evaluated after six weeks of treatment according to RECIST standards. For adverse events, the NCI-CTC3.0 was applied. Result There were 11 cases that were qualified for efficacy evaluation and 15 cases for safetyevaluation. Among the 11 cases included in efficacy evaluation, there were 8 cases achieving SD and 3 cases of PD.The disease control rate was 72.2%（8/11）. The safety evaluation results showed that the incidence of skin rash related to nimotuzumab was low, and which was in no association with clinical benefit. All adverse events related with nimotuzumab were mild. Conclusion Nimotuzumab combined with chemotherapy or radiotherapy for patients with NSCLC increases disease control rate and has a better safety profile.